Regarding the potential treatment strategies for Farber disease/SMA-PME, enzyme replacement therapy with recombinant acid ceramidase therapy and gene replacement therapy with ASAH1 cDNA are currently being investigated [152,156]. This evidence concerns the gene ASAH1 and progressive myoclonus epilepsy.